Composition for the transdermal delivery of lerisetron

Details Composition for the transdermal delivery of lerisetron Composition for the transdermal delivery of lerisetron

1999-10-19

2000-10-24

Henley, III, Raymond

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

424449, A61K 31495, A61K 970

Patent

active

061368075

ABSTRACT:
The present invention provides a transdermal drug delivery composition comprising:
(a) a copolymer of one or more (meth)acrylate monomers being selected from the group consisting of alkyl acrylates containing 4 to 12 carbon atoms in the alkyl group and alkyl methacrylates containing 4 to 12 carbon atoms in the alkyl group and one or more hydrophilic monomers being copolymerizable with said (meth)acrylate monomers, and
(b) a therapeutically effective amount of lerisetron. The transdermal drug delivery composition is used to make a transdermal drug delivery device for the delivery of lerisetron.

REFERENCES:
patent: Re24906 (1960-12-01), Ulrich
patent: 3786116 (1974-01-01), Milkovich
patent: 3842059 (1974-10-01), Milkovich et al.
patent: 4732808 (1988-03-01), Krampe et al.
patent: 5011928 (1991-04-01), Venero et al.
patent: 5051510 (1991-09-01), Venero et al.
patent: 5256665 (1993-10-01), Orjales-Venero et al.
patent: 5322850 (1994-06-01), Orjales-Venero
patent: 5672604 (1997-09-01), Orjales-Venero

Affiliated with

Also associated with

Rating

Composition for the transdermal delivery of lerisetron does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Composition for the transdermal delivery of lerisetron, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for the transdermal delivery of lerisetron will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1964242